Apart from the neurofilaments, we found a fraction of markers, namely Aβ1–42, NPY, UCHL1, and GOT1, which not only discriminated SOD1‐ALS from controls, but whose levels were also partially “corrected” by 3‐month treatment with tofersen, thus qualifying them as potential diagnostic markers and indicators of the early treatment response. This evidence concerns the gene NPY and amyotrophic lateral sclerosis.